Page 66 - Read Online

Page 28 of 36 Dave et al. J Cancer Metastasis Treat 2020;6:46 I http://dx.doi.org/10.20517/2394-4722.2020.106

8. Pezzuto JM, Vang O. Perspective: a positive cocktail effect of the bioactive components in the diet. Natural Products for Cancer
Chemoprevention. Springer; 2020. p. 615.
9. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
10. Baena Ruiz R, Salinas Hernández P. Cancer chemoprevention by dietary phytochemicals: Epidemiological evidence. Maturitas
2016;94:13-9.
11. Howes MJ, Simmonds MS. The role of phytochemicals as micronutrients in health and disease. Curr Opin Clin Nutr Metab Care
2014;17:558-66.
12. Aunan JR, Cho WC, Søreide K. The biology of aging and cancer: a brief overview of shared and divergent molecular hallmarks. Aging
Dis 2017;8:628-42.
13. Kotecha R, Takami A, Espinoza JL. Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence. Oncotarget
2016;7:52517-29.
14. Stevenson DE, Hurst RD. Polyphenolic phytochemicals--just antioxidants or much more? Cell Mol Life Sci 2007;64:2900-16.
15. Trela BC, Waterhouse AL. Resveratrol: isomeric molar absorptivities and stability. J Agric Food Chem 1996;44:1253-7.
16. Jeandet P, Douillet-Breuil AC, Bessis R, Debord S, Sbaghi M, Adrian M. Phytoalexins from the vitaceae: biosynthesis, phytoalexin gene
expression in transgenic plants, antifungal activity, and metabolism. J Agric Food Chem 2002;50:2731-41.
17. Singh CK, Liu X, Ahmad N. Resveratrol, in its natural combination in whole grape, for health promotion and disease management. Ann N
Y Acad Sci 2015;1348:150-60.
18. Maier-Salamon A, Böhmdorfer M, Thalhammer T, Szekeres T, Jaeger W. Hepatic glucuronidation of resveratrol: interspecies comparison
of enzyme kinetic profiles in human, mouse, rat, and dog. Drug Metab Pharmacokinet 2011;26:364-73.
19. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 1997;30:91-113.
20. Sato M, Maulik G, Bagchi D, Das DK. Myocardial protection by protykin, a novel extract of trans-resveratrol and emodin. Free Radic
Res 2000;32:135-44.
21. Soleas GJ, Diamandis EP, Goldberg DM. Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal
1997;11:287-313.
22. Nonomura S, Kanagawa H, Makimoto A. Chemical constituents of polygonaceous plants. I. studies on the components of Ko-J O-Kon.
(Polygonum Cuspidatum Sieb. Et Zucc.). Yakugaku Zasshi 1963;83:988-90.
23. Chung MI, Teng CM, Cheng KL, Ko FN, Lin CN. An antiplatelet principle of veratrum formosanum. Planta Med 1992;58:274-6.
24. Crozier A, Jaganath IB, Clifford MN. Dietary phenolics: chemistry, bioavailability and effects on health. Nat Prod Rep 2009;26:1001-43.
25. Lançon A, Delmas D, Osman H, Thénot JP, Jannin B, Latruffe N. Human hepatic cell uptake of resveratrol: involvement of both passive
diffusion and carrier-mediated process. Biochem Biophys Res Commun 2004;316:1132-7.
26. Wang LX, Heredia A, Song H, et al. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and
anti-HIV activity. J Pharm Sci 2004;93:2448-57.
27. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug
Metab Dispos 2004;32:1377-82.
28. Boocock DJ, Patel KR, Faust GE, et al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by
high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2007;848:182-7.
29. Urpi-Sarda M, Zamora-Ros R, Lamuela-Raventos R, et al. HPLC-tandem mass spectrometric method to characterize resveratrol
metabolism in humans. Clin Chem 2007;53:292-9.
30. Zamora-Ros R, Urpí-Sardà M, Lamuela-Raventós RM, et al. Diagnostic performance of urinary resveratrol metabolites as a biomarker of
moderate wine consumption. Clin Chem 2006;52:1373-80.
31. Pattus F, Rothen C, Streit M, Zahler P. Structure, composition, enzymatic activities of human erythrocyte and sarcoplasmic reticulum
membrane films. Biochim Biophys Acta 1981;647:29-39.
32. Yáñez M, Fraiz N, Cano E, Orallo F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and
on monoamine oxidase activity. Biochem Biophys Res Commun 2006;344:688-95.
33. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005;49:472-81.
34. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992;339:1523-6.
35. Pezzuto JM. Grapes and human health: a perspective. J Agric Food Chem 2008;56:6777-84.
36. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science
1997;275:218-20.
37. Pezzuto JM. Resveratrol: twenty years of growth, development and controversy. Biomol Ther (Seoul) 2019;27:1-14.
38. Gambini J, Inglés M, Olaso G, et al. Properties of resveratrol: in vitro and in vivo studies about metabolism, bioavailability, and biological
effects in animal models and humans. Oxid Med Cell Longev 2015;2015:837042.
39. Pezzuto JM, Kondratyuk TP, Ogas T. Resveratrol derivatives: a patent review (2009 - 2012). Expert Opin Ther Pat 2013;23:1529-46.
40. Park EJ, Pezzuto JM. The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta 2015;1852:1071-113.
41. Wadsworth TL, Koop DR. Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW
264.7 macrophages. Biochem Pharmacol 1999;57:941-9.
42. Rotondo S, Rajtar G, Manarini S, et al. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear
leukocyte function. Br J Pharmacol 1998;123:1691-9.
43. Das S, Alagappan VK, Bagchi D, Sharma HS, Maulik N, Das DK. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol
consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol 2005;42:281-9.